ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown
Published: May 19, 2025
The intricate pathologic features of Parkinson's disease (PD) coupled with the obstacle posed by blood-brain barrier (BBB) significantly limit efficacy most medications, leading to difficulties in PD treatments. Herein, we have developed a nanomedicine based on stem-cell-derived exosomes coloaded hydroxyl-terminated phosphorus dendrimers (AK76) and quercetin (Que) for combined therapeutic intervention PD. engineered nanocomplexes (for short, QAE NPs) exhibit an optimal size 269.7 nm, favorable drug release profile, desired cytocompatibility, enabling penetration nasal mucosa accumulate brain without BBB crossing. NPs can scavenge reactive oxygen species, promote M2 microglial polarization, attenuate inflammation, protect neurons inducing autophagy restoring mitochondrial homeostasis through integrated anti-inflammatory antioxidant properties exosomes, Que AK76, collectively improved motor functions, coordination, alleviation depression-like symptoms mice. formulated several components are able simultaneously modulate both microglia neurons, offering promising potential treatment other neurodegenerative disorders.
Language: Английский